RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
変異株が現れる度に既存ワクチンへの有効性も考えなくてはならないですね。mRNAの技術で素早い応用は出来ると思いますが,今後もどのような変異株が出現してくるか注目です。 Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 https://t.co/liIKejc2MS
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
RT @iina_kobe: こんなレベルでネイチャー載るのか。。。
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 | Nature https://t.co/osmBdRSR0W
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
RT @UmZ1paZbmB6KpPV: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio https://t.co/GEzgkH58Ub
Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio https://t.co/GEzgkH58Ub
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
こんなレベルでネイチャー載るのか。。。
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
네이처 하이라이트:SARS-CoV-2 변이 B.1.351 및 B.1.1.7의 항체 내성 https://t.co/Pu3ozA0cEu
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
ブラジル変異株は要注意
Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio https://t.co/0czjtUZaKE
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
B.1.351変異株は、N末端ドメインに対するモノクローナル抗体による中和に抵抗性であるだけでなく、受容体結合ドメインの受容体結合モチーフに対する多数の患者由来モノクローナル抗体による中和にも抵抗性を示す。これは主としてE484K置換を引き起こす変異のためである。
野生型のSARS-CoV-2に比べると、B.1.351株は回復期血漿やワクチン既接種者由来血清による中和に対して、抵抗性が著しく高いことが分かった(前者に対しては9.4倍、後者に対しては10.3~12.4倍)。 SARS-CoV-2の変異株B.1.351とB.1.1.7の抗体抵抗性 | Nature https://t.co/GqEXpYwOw4
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
RT @NatureJapan: Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature https://t.co/ndGWEKJsHa #コロナウイルス #SARSCoV2 #変異株
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 https://t.co/9FNEKGQn6x Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies https://t.co/v4h4YFwewT 株によるんだろうけど今日のネーチャーでも実験的にはワクチンを回避する可能性が指摘されている
コロナから回復した人も、英国型変異株にはかかりづらいけど、南ア型変異株だとかかるかもしんないってことか。 もう一歩進んだ研究報告が出てきてるなぁ。 Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio https://t.co/syuF0Xma6T
RT @coasa: "Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio" https://t.co/P5OiEbHMDj
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
#カガク。#医。#生体分子。#変異。#感染。新型コロナウイルス(SARS-CoV-2|COVID-19)。スパイク糖タンパク質。Nature ハイライト「コロナウイルス:SARS-CoV-2の現在拡散中で懸念されている変異株…」https://t.co/GpyQYnNv9V “B.1.1.7変異株とB.1.351変異株”。K417N・E484K・N501Y変異。PDB 6ZGG。
"Nature ハイライト:SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 | Nature | Nature Portfolio" https://t.co/P5OiEbHMDj
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
RT @science_jp: コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
コロナウイルス: SARS-CoV-2の現在拡散中で懸念されている変異株に対する中和活性 (Nature Research) https://t.co/AhXzGiO92F
@Leonthehitman7 @zerocovidzoe @DmodosCutter @dgurdasani1 @IndependentSage https://t.co/rDML8RB7Z8: "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by ... sera from individuals who have been vaccinated (10.3–12.4-fold
@a_meluzzi Professore,perché vaccinano per una spike che probabilmente non esiste più?!Perché pur essendoci studi che dimostrano una scarsa efficacia per le varianti,che sembra stiano prendendo il sopravvento, continuano ad osannare questa sperimentazione
Study of coronavirus variants predicts virus evolving to escape current vaccines https://t.co/9DnQLsCi7p https://t.co/CO1I9Omle8 https://t.co/CFtd27gCxV
@Kevin1982 👇👇👇
@jorjan333 @Kevin1982 @pro__lockdown No, see https://t.co/rDML8RB7Z8: "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by ... sera from individuals who have been vaccinated (10.3–12.4-fold)". (That includes the effect
Resistencia a los anticuerpos de las variantes B.1.351 y B.1.1.7 del SARS-CoV-2 https://t.co/wWAZ3MM7wT
RT @HarrySpoelstra: #501YV2 is and remains a potential (vaccine)immunity problem, also for #Belgium #vaccination #caution https://t.co/HxEl…
#501YV2 is and remains a potential (vaccine)immunity problem, also for #Belgium #vaccination #caution
RT @nanogenomic: See also for South Africa strain (501.V2): https://t.co/Pu5koqJYt8 “Moreover, compared to wild-type SARS-CoV-2, B.1.351…
RT @nanogenomic: See also for South Africa strain (501.V2): https://t.co/Pu5koqJYt8 “Moreover, compared to wild-type SARS-CoV-2, B.1.351…
See also for South Africa strain (501.V2): https://t.co/Pu5koqJYt8 “Moreover, compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.
@EmilyPetro22 @PerthshireMags @globalhlthtwit "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.3–12.4-fold)": https://t.co/rDML8
RT @PDroger08: 6. vaccine efficacy against mutated strains https://t.co/e94XLdULvR
RT @PDroger08: 6. vaccine efficacy against mutated strains https://t.co/e94XLdULvR
RT @PDroger08: 6. vaccine efficacy against mutated strains https://t.co/e94XLdULvR
@PerthshireMags @globalhlthtwit Vaccines have only limited effect on transmission and #LongCovid rates. There are also numerous vaccine-resistant variants: https://t.co/rDML8RB7Z8
@Garrardinho No, the data shows that "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) *and* sera from individuals who have been vaccinated (10.3–12.4-fold)": https://t.co/rDML8RB7Z8
6. vaccine efficacy against mutated strains https://t.co/e94XLdULvR
RT @amrit_lohia: @Pace1013 @JohnWest_JAWS Firstly, focusing on "hospitalisation / deaths" totally ignores the major problem of permanent or…
@TransGeraldine @Pace1013 @JohnWest_JAWS That's very kind but I am not a scientist, merely an interested amateur. That is why I have repeatedly referred to the paper by Wang et al (https://t.co/rDML8RB7Z8) in support of what I am saying.
@Pace1013 @JohnWest_JAWS Firstly, focusing on "hospitalisation / deaths" totally ignores the major problem of permanent organ damage, i.e. #LongCovid. Secondly, there are now numerous VACCINE-RESISTANT variants, as shown by the current waves in India and C
新型コロナウイルスのB.1.351変異株(南アフリカ共和国で最初に検出された)とB.1.1.7変異株(英国で最初に検出された)は、抗体による中和に対する抵抗性が高まっていることが実験室での実験によって明らかになった。 :https://t.co/WWxonBq7n6
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 | Nature https://t.co/GNLfK1fbte
RT @Santal68: @valy_s @BagueraDaniela ecco qui il link corretto : https://t.co/v3J18JW75W
@pro__lockdown @MusingsOfYouth @sparky20211 @eugyppius1 @devisridhar @dgurdasani1 @chrischirp Yes... We already had this study: https://t.co/rDML8RjwAy on B.1.1.7 and B.1.351, and now B.1.617 (Indian variant) is suspected to be similar: https://t.co/ICKYOQ
RT @amrit_lohia: @sparky20211 @pro__lockdown "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by con…
これか!うむ〜。 Moreover, compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.3–12.4-fold) https://t.co/t8EqG9FhSC
@sparky20211 @pro__lockdown The person you quote is simply wrong. Again, see https://t.co/rDML8RB7Z8
@sparky20211 @pro__lockdown "compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.3–12.4-fold)": https://t.co/rDML8RB7Z8
@DigiFill @guardian This simply incorrect. Please stop the spread of misinformation. https://t.co/6a2CkAg6iR
@mr_Smith_Econ @eisema @markvanasten @Diedhein @hanszandvliet79 @rubenivangaalen Hier staat dat mutaties aan de vaccins ontsnappen. https://t.co/RwguYlr0Q7 Stond ook in Gezond Verstand geloof ik. Gelukkig dat onze volksgezondheid in handen van Marc Janssen
@pontyboi @dtks888 @BorisJohnson_MP Wrong. The decrease is due to the last lockdown, and there are now many variants which have evolved to become highly resistant to vaccines: https://t.co/rDML8RB7Z8
@przemekg18 Focusing on "hospitalisations/deaths" is simply incorrect: it ignores the many "young, low risk" individuals suffering from permanent organ damage (Long Covid): see https://t.co/FowM4FuzEQ. Also ignores the evolution of vaccine-resistant varian
@TobyDiego Long Covid (permanent organ damage), have you heard of it? And BTW there are many variants which are becoming highly resistant to vaccines: see e.g. https://t.co/rDML8RB7Z8
@mikegehard This article cites a 9.4x concentration against the same variant. https://t.co/bERAJk1uxo
B.1.351変異株(南アフリカ共和国で最初に検出された)とB.1.1.7変異株(英国で最初に検出された)の研究→ SARS-CoV-2:B.1.351、B.1.1.7変異株は抗体による中和に強く抵抗することが実験室で判明した | Nature | Nature Portfolio: https://t.co/gyKxFwXy10
RT @DavidWa59907969: Our govt has bet the farm on vaccines, and it's becoming increasingly clear the vaccines are not a solution. #COVIDze…
Estudo completo https://t.co/KARtamkFvV
@hodgsonbrian05 "Mutationally, this virus is going in a direction that could ultimately lead to escape from our current therapeutic and prophylactic interventions that are directed against the viral spike protein". https://t.co/E33JRiB3jQ
Our govt has bet the farm on vaccines, and it's becoming increasingly clear the vaccines are not a solution. #COVIDzero saves lives and livelihoods. @CDCofBC @adriandix #BCpoli #COVID19
RT @chiw00k: 안타까운 소식입니다. 지금 걱정스러운 코비드 바이러스 변종이 두 개가 있어요. 영국변종과 남아공변종이지요. 기존 코비드 바이러스에 면역이 생긴 사람들의 항체를 분석해 보니 영국변종에는 어느 정도 작용을 하는데 남아공변종에는 영…
@MartinThornber @terrence_mccoy @DrZoeHyde Agree. Nuance lost on twitter. We had a catastrophic 2nd/3rd wave due to wishful thinking and dithering at the top combined with a more infectious variant. Sad to see others making the same mistakes. P1 has E484
2) Lite relaterade trådar här på Twitter. Om Pfizers preliminärt rapporterade skydd mot B.1.351: https://t.co/3wvEHN0sLU
@RosemaryFreiTO @Malfunctionin21 @Matthews_angst @magicbu92001094 True you are critiquing Bridle's statement while Bridle provided a study in Nature dated March 8, 2021 to substantiate his claim while so far you haven't provided any references. Call me cra
4) Here's a related thread on protection against variants - note that new data from Pfizer indicates protection against B.1.351 in real world settings (scroll down): https://t.co/8ZlbafU4Nx
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 https://t.co/n2aN49zVUt
@judithfinch @robinmonotti https://t.co/5ZOTlEEdC9 do the math A 12.4 fold reduction equates to a 92% reduction in effectiveness, while a 10.3 fold reduction equates to a 90.3% lowering. I have one smart ass, damn.
@robinmonotti https://t.co/5ZOTlEEdC9 A 12.4 fold reduction equates to a 92% reduction in effectiveness, while a 10.3 fold reduction equates to a 90.3% lowering.
@Debi259 @robinmonotti https://t.co/5ZOTlEEdC9 Happy to do so!
@WilkinsonJamesD @robinmonotti https://t.co/5ZOTlEEdC9 Educate yourself too. It doesn't really take much logic to figure out vaccines can't be enough effective towards new strains.
@ProfPatch83 @Savion Moderna and pfizer are also ineffective on the sa variant (10 to 12% on SA as opposed to 90+% on the rest). That's why moderna started making a SA variant specific booster. https://t.co/6o5mBeOdyR
RT @Rose_Marie_Holt: @NicoleSGrigg @Phoenixwmn This is a variant that in vitro is concerning for decreased effectiveness of monoclonal anti…
@NicoleSGrigg @Phoenixwmn This is a variant that in vitro is concerning for decreased effectiveness of monoclonal antibodies & current vaccines. https://t.co/HdeET24WvS
Wenn wir uns mit dem Impfen nicht beeilen, wird bei Ausbreitung der südafrikanischen B.1.351 Variante sehr viel weniger Schutz vorhanden sein https://t.co/hXcPCx9JHV
A new study of the UK & South Africa variants predicts that current vaccines & certain monoclonal antibodies may be less effective at neutralizing these variants & that new variants raise the specter that reinfections could be more likely @WHCO
SARS-CoV-2:B.1.351、B.1.1.7変異株は抗体による中和に強く抵抗することが実験室で判明した | Nature | Nature Portfolio: https://t.co/8zhj4EB89R
RT @nature: The B.1.351 and B.1.1.7 SARS-CoV-2 variants (first detected in South Africa and the UK, respectively) show increased resistance…
@RandPaul B.1.351 South African variant is and has been the one showing a pattern of not only increased transmissibility but worse outcomes, with experimental evidence of significant vaccine resistance... Oh look, it's not in your study! https://t.co/f0Jj